Indeed, peripheral blood blasts of AML patients receiving standard decitabine monotherapy (20 mg/m2 daily for 10 days) showed increased NY-ESO-1 and MAGEA3/A6 expression regardless of clinical response, along with promoter-specific and global (LINE-1) hypomethylation. The gene discussed is MAGEA3; the disease is acute myeloid leukemia.